ID | 1530 | |
PMID | 21310913 | |
Year | 2011 | |
Sequence | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | |
Name | Flagellin | |
Length | 393 | |
N-Terminal Modification | Free | |
C-Terminal Modification | Free | |
Linear/ Cyclic | Linear | |
Chirality | L | |
Chemical Modification | None | |
Origin of Peptide | Flagellin was prepared from P. aeruginosa strain PA01 or PAK | |
Nature of Peptide/Cargo | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | |
Mechanism | Flagellin was prepared from P. aeruginosa strain PA01 or PAK | |
Cargo Sequence/Structure | None | |
Name of cargo | Not applicable | |
Assay | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | |
Enhancer | PBS | |
Properties of enhancer | Not mentioned | |
Concentration | 500ng in 5µl of PBS | |
Incubation time | 1 day post-infection | |
Tissue permeability (value with units) | Clinical score of Flagellin is slightly more than PBS control, both approximating to 9.1 and 8.9 respectively. | |
Tissue Sample | Eyes of TLR5-/- mouse breeding pairs | |
Ex vivo/In vivo/In vitro | in vitro | |
STRUCTURE |
| |
SMILES | N.A. |